Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to $636000.0.

  • Bolt Biotherapeutics' Amortizatization of Intangibles rose 1777.78% to $636000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 4024.73%. This contributed to the annual value of $2.6 million for FY2024, which is 4179.84% down from last year.
  • Bolt Biotherapeutics' Amortizatization of Intangibles amounted to $636000.0 in Q3 2025, which was up 1777.78% from $624000.0 recorded in Q2 2025.
  • In the past 5 years, Bolt Biotherapeutics' Amortizatization of Intangibles registered a high of $1.3 million during Q3 2023, and its lowest value of -$4.6 million during Q4 2021.
  • In the last 5 years, Bolt Biotherapeutics' Amortizatization of Intangibles had a median value of $682000.0 in 2022 and averaged $502842.1.
  • As far as peak fluctuations go, Bolt Biotherapeutics' Amortizatization of Intangibles crashed by 94824.4% in 2021, and later skyrocketed by 12094.34% in 2022.
  • Over the past 5 years, Bolt Biotherapeutics' Amortizatization of Intangibles (Quarter) stood at -$4.6 million in 2021, then skyrocketed by 115.36% to $705000.0 in 2022, then surged by 69.36% to $1.2 million in 2023, then tumbled by 78.98% to $251000.0 in 2024, then skyrocketed by 153.39% to $636000.0 in 2025.
  • Its Amortizatization of Intangibles was $636000.0 in Q3 2025, compared to $624000.0 in Q2 2025 and $615000.0 in Q1 2025.